Worth mentioning is our EpCAM-independent isolation strategy, which involves recognizing MUC1, thus facilitating the capture of EpCAM-negative CTCs from metastatic BC patients (Patient No. 16, No. 72 and No. 88, Supplementary Fig. 19 and Supplementary Data 1). Here, EPCAM is linked to breast cancer.